Actively Recruiting
Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario
Led by Consorzio Oncotech · Updated on 2025-02-20
300
Participants Needed
21
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a retrospective and prospective, multicenter, observational, two-cohorts study aimed to evaluate clinical outcomes and safety of patients diagnosed with advanced high grade ovarian cancer whose tumor was tested for the homologous recombination (HR) status using a validated HR deficiency test between January 2021 and January 2026. * Cohort A: Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy. * Cohort B: Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice.
CONDITIONS
Official Title
Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female, age 18 years or older at diagnosis
- Diagnosed with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer
- Tumor tested with a validated homologous recombination deficiency test between January 2021 and January 2026
- Patients with HRD score > 42 or high Loss of Heterozygosity score treated with Bevacizumab and Olaparib after first-line platinum-based chemotherapy enrolled in Cohort A
- Patients with HRD score < 42 or low Loss of Heterozygosity score treated with first-line platinum-based chemotherapy with or without bevacizumab or other targeted agents enrolled in Cohort B
- Able to understand study procedures and provide written informed consent
You will not qualify if you...
- Have not undergone a validated homologous recombination test on tumor sample
- Have germline or somatic BRCA 1 or 2 mutations
- Deceased at the time of study inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.
Bari, BA, Italy, 70124
Actively Recruiting
2
Azienda Ospedaliero Universitaria di Bologna - Policlinico S.Orsola-Malpighi
Bologna, BO, Italy, 40138
Actively Recruiting
3
Azienda Ospedaliera S.Croce e Carle Cuneo
Cuneo, CN, Italy, 12100
Actively Recruiting
4
Azienda Ospedaliera per l'emergenza Cannizzaro
Catania, CT, Italy, 95100
Actively Recruiting
5
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
Meldola, FC, Italy, 47014
Actively Recruiting
6
Azienda Ospedaliero Universitario Careggi
Florence, FI, Italy, 50134
Actively Recruiting
7
IRCCS Policlinico San Martino
Genova, GE, Italy, 16132
Actively Recruiting
8
Fondazione IRCCS San Gerardo dei Tintori (Monza)
Monza, MB, Italy, 20900
Not Yet Recruiting
9
Università Vita-Salute San Raffaele (IRCCS San Raffaele - Milano)
Milan, MI, Italy, 20132
Actively Recruiting
10
Istituto Nazionale Tumori (INT) - Milano
Milan, MI, Italy, 20133
Actively Recruiting
11
Istituto Oncologico Veneto (IOV)
Padova, PD, Italy, 35128
Actively Recruiting
12
Ospedale S. Maria della Misericordia
Perugia, PG, Italy, 06156
Actively Recruiting
13
Centro di riferimento oncologico - CRO di Aviano
Aviano, PN, Italy, 33081
Actively Recruiting
14
Istituto Nazionale Tumori Regina Elena - Roma
Roma, RM, Italy, 00144
Actively Recruiting
15
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, RM, Italy, 00168
Actively Recruiting
16
Ospedale San Paolo - ASL2 - Savona
Savona, SV, Italy, 17100
Actively Recruiting
17
Ospedale Mauriziano Umberto I
Torino, TO, Italy, 10128
Actively Recruiting
18
Azienda sanitaria universitaria Friuli Centrale (ASU FC)
Udine, UD, Italy, 33100
Actively Recruiting
19
Azienda Ulss 3 Serenissima
Mestre, VE, Italy, 30174
Actively Recruiting
20
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale
Naples, Italy, 80131
Actively Recruiting
21
Università degli Studi di Napoli "Federico II"
Naples, Italy, 80131
Actively Recruiting
Research Team
M
Michele B Michele Bartoletti, MD
CONTACT
B
BeLIVE S BeLIVE Service
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here